Delivery Order SPE2DB24D2205-SPE2DB25FEHRB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for supply of Envarsus XR 4 mg tablets (100 count) under a firm fixed price contract valued at $2,141.57. This delivery order represents a non-set-aside competitive award, with an ultimate completion date of September 3, 2025. The pharmaceutical products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,288.86 for Envarsus XR 1 mg tablets (100-count) with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) under a firm fixed-price contract valued at $4,712.76, with completion targeted for September 10, 2025. This non-set-aside award represents a competitive procurement of pharmaceutical products to support federal healthcare needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical supplier within the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,581.30 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count package) under a firm fixed-price contract. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 15, 2025. AmerisourceBergen will fulfill this requirement from its corporate office location in Conshohocken, Pennsylvania, where the company is headquartered as a major...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,718.48 for 100 tablets of Envarsus XR 1 mg on July 28, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price, competitively awarded contract involves pharmaceutical delivery to support federal medical procurement needs. The contract does not include a set-aside designation and is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate headquarters...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Envarsus XR 0.75 mg tablets (30-count) with a ceiling value of $2,339.52. This delivery order represents a competitive, firm fixed-price procurement with no set-aside designation and is scheduled for ultimate completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on July 15, 2025, for ENVARSUS XR 4 mg tablets (100 count). The contract is valued at $1,841.40 under a firm fixed price arrangement with an ultimate completion date of August 5, 2025. This award represents a non-set-aside competitive procurement and serves as a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for completion by October 7, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a non-set-aside competitive procurement, reflecting AmerisourceBergen's established capability to...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on June 20, 2025, with a ceiling value of $1,711.95. The award covers the supply of Envarsus XR 4 mg tablets in a 100-count quantity, with an ultimate completion date of July 14, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded through competitive procedures. The contract is classified...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on May 8, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply Envarsus XR 1 mg tablets (30-count) at a ceiling value of $1,553.40. The contract is a firm fixed-price delivery order with an ultimate completion date of May 30, 2025, and was competitively awarded without set-aside designation. This award represents a child contract under...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHRBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 4 mg tablets (100-count) valued at $10,271.70 under firm fixed price terms. The delivery order was competitively awarded without set-aside designation and is scheduled for completion by October 7, 2025. AmerisourceBergen will perform this work from its corporate headquarters in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor supporting federal medical procurement across the defense and civilian healthcare sectors. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 billion through December 2026. The prime IDC vehicle provides comprehensive pharmaceutical and medical supply support globally to military healthcare systems and other federal agencies including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen's extensive portfolio of federal contracts demonstrates established capability in delivering a broad range of pharmaceutical products, medical devices, and healthcare commodities through open competition, positioning the company as a critical vendor within the federal medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 9/16/25 |